Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma
Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma
Not yet recruiting · NCT06671717 · Registry updated 2024-11-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm | Not yet recruiting | Not applicable | 2024-11-06 | NCT06671717 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Peking University People's Hospital | 269 |
| Ruijin Hospital | 454 |
| West China Hospital | 359 |
| Wuhan TongJi Hospital | 29 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Peking University, Institute of Hematolgoy, Beijing, | Beijing | China | 1 |